Management & Scientific Team

PIYUSH GUPTA, PhD

Co-Founder, CEO & Chairman

Dr. Gupta earned his bachelor’s degree in Mathematics from the University of Chicago and a PhD in Cancer Biology from MIT. Dr. Gupta is a member of the Whitehead Institute for Biomedical Research and an Associate Professor of Biology at MIT. Dr. Gupta previously co-founded Verastem, Inc., based on his scientific research at MIT and served as a Director on its corporate board from founding through multiple rounds of venture capital financing and an IPO. His research has appeared in leading scientific journals and received international acclaim, including coverage by the MIT Technology Review, Bloomberg News, and as a lead story in the New York Times.


PHIL STEPHENS, PhD

President & Chief Scientific Officer

Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and brings a breadth of experience in life sciences and the clinical diagnostics and laboratory industries. Dr. Stephens was Chief Scientific Officer at Foundation Medicine Inc (FMI) for 5 years where he oversaw the development of comprehensive next generation sequencing cancer diagnostic assays in the CLIA setting. During his seven years at FMI, he also played an integral role in securing reimbursement of their novel products, driving 30+ Pharmaceutical collaborations and the FDA approval coupled with Medicare reimbursement of FoundationOneTM. Prior to joining Naveris, Dr. Stephens was Chief of Cancer Biology at Grail.


THOMAS K. LIEM, MST/ MBA

Senior Vice President, Business Operations & Finance

Thomas K. Liem is Senior Vice President of Business Operations & Finance. Prior to joining Naveris, Mr. Liem was at Thomas H. Lee Partners for seven years where he managed financial reporting, portfolio monitoring, fundraising and operations initiatives and was an integral part of the firm’s fundraising efforts. He has over 20 years of finance and business operations experience at companies such as Nuance Communications, State Street Corporation, Fidelity Investments, The MathWorks Inc, Percussion Software, The World Bank and The Hackett Group. Mr. Liem received his BA with honors from Hamilton College, an MBA from Babson College F.W. Olin Graduate School of Business and an MS in Taxation from Suffolk University, where he was a Graduate Fellow


PHILIP HAYDON, PhD

Co-Founder, Director

Dr. Haydon is the Annetta and Gustav Grisard Professor and Chair in the Department of Neuroscience at Tufts. He is an internationally recognized  leader in the study of neuron-glial interactions in disease.  He has received several prestigious awards, including a McKnight Investigator Award and the Jacob Javits Award from the National Institutes of Neurological Disorders and Stroke. Dr. Haydon was a founder and partner in Prairie Technologies, a privately held company that developed state-of-the-art microscopy tools including 2 Photon microscopes for use in the neurosciences. Prairie Technologies was subsequently acquired by Bruker Instruments. He was also co-founder and President of GliaCure, Inc., which has developed a small molecule modulator of the P2Y6R as a potential therapeutic for Alzheimer’s disease and asthma. Dr. Haydon has taken this company through successful rounds of fund raising and has overseen preclinical and clinical development of the compounds.


STEPHEN NABER, MD/PhD

Medical Director

Stephen Naber, MD, PhD is   Laboratory and Medical Director. Dr. Naber is a Board certified Anatomic Pathologist with expertise in cancer diagnostics.  Prior to joining Naveris, Dr. Naber served as the Chief of Pathology at Tufts Medical Center  and was Director of its CLIA & CAP accredited diagnostic lab. Dr. Naber serves as an Associate Chair in the Department of Pathology at Tufts University School of Medicine, and has had a long and illustrious teaching and research career spans more than two decades. He serves as Member of Scientific Advisory Board of BioLegend CNS, Inc. He has been the recipient of several National Institutes of Health and Department of Defense grants and awards for studies in studies of breast neoplasia, models of tumor development, and regulation of gene expression in human breast cancer. Dr. Naber received his MD from St. Louis University School of Medicine and his PhD in Physiology from the University of Houston.


CHARLOTTE KUPERWASSER, PhD

Dr. Kuperwasser is a Professor of Developmental, Molecular & Chemical Biology and Director of the Raymond & Beverly Sackler Convergence Laboratory at Tufts University School of Medicine. She has over 20 years of experience in leading cancer R&D laboratories. Dr. Kuperwasser  pioneered the development of innovative models of cancer and discovered  biomarkers for early detection of breast cancer. Dr. Kuperwasser received her PhD at the University of Massachusetts, Amherst, and was a Jane Coffin Child’s Postdoctoral Fellow at the Whitehead Institute for Biomedical Research at MIT. She has also been a Howard Hughes Fellow, a Merck Fellow, and received multiple awards for her research including the ECOG/Aventis Young Investigator Award. She has authored more than 100 publications and serves as an external editor and reviewer for multiple scientific journals, the National Institutes of Health, and the American Cancer Society.


GAORAV GUPTA, MD/PhD

Inventor & Co-Chair, Scientific Board of Advisors

Dr. Gaorav Gupta is a UNC Lineberger Comprehensive Cancer Center member and Assistant Professor in the Division of Radiation Oncology at UNC-Chapel Hill School. He received his M.D. and Ph.D. from Weill Cornell Medical College of Cornell University. He was Chief Resident in Radiation Oncology at Memorial Sloan Kettering Cancer Center and was among the few 2013 recipients of the Burroughs Wellcome Fund Career Award for Medical Scientists. Dr. Gupta  lab studies DNA repair processes in cancer development, metastatic progression, and responses to therapy.


BHISHAM CHERA, MD

Co-Chair, Scientific Board of Advisors

Bhisham Chera, MD is an Associate Professor and Associate Chair in the Department of Radiation Oncology at the University of North Carolina School of Medicine.  He received his M.D. from the Medical University of South Carolina. He is the leader of the head and neck radiation oncology program at the University of North Carolina School of Medicine and a clinical trials specialist and with clinical and academic expertise is in the field of head and neck oncology and healthcare quality improvement and patient safety. Dr. Chera has conducted three phase II clinical trials evaluating de-intensified chemoradiotherapy, and pioneered the innovation of treating patients with a substantial reduction of both radiation and chemotherapy.


ROBERT WEINBERG, PhD

Scientific Advisor

Dr. Robert A. Weinberg is a Founding Member of Whitehead Institute for Biomedical Research and the Daniel K. Ludwig Professor for Cancer Research in the Department of Biology at MIT.  He is world renown for his expertise and vision in the basic understanding of the mechanisms that underlie cancers.  Dr. Weinberg is the Author or Editor of five books and more than 350 articles.  He is an elected Member of the U.S. National Academy of Sciences and the Institute of Medicine and is a Fellow of the American Academy of Arts and Sciences. Among his honors are the National Academy of Sciences/U.S. Steel Foundation Award in Molecular Biology, the Sloan Prize of the General Motors Cancer Research Foundation, the Bristol-Myers Award for Distinguished Achievement in Cancer Research, the Landon Prize of the American Association for Cancer Research, the Gairdner Foundation International Award, the Keio Medical Foundation Prize, 1997 National Medal of Science and the Otto Warburg Medal in 2007.  Dr. Weinberg is Co-Founder of Verastem, Inc. and serves as its Chair of Scientific Advisory Board and served as its Co-Chair of Scientific Advisory Board.